ProtoKinetix, Incorporated Announces Investigator Sponsored Clinical Trial Submitted to Health Canada for the use of AAGP™ in the Treatment of Type 1 Diabetes

Jan 17, 2017, PKTX OTC Disclosure & News Service ProtoKinetix, Incorporated (OTC: PKTX) (the Company or ProtoKinetix ) (www.protokinetix.com) today announced that the Governors of the University of Alberta have submitted an Investigational Testing Authorization application to commence clinical studies in Canada. This authorization will allow the clinical trial group to enroll Canadian patients into the study. “Based on extensive experiments in the lab we are clearly excited to take forward the AAGP™ molecule from the bench to testing in
http://bit.ly/2jGNa8M